featured
Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel–Trastuzumab in Uterine Serous Carcinomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared With Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas That Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Clin. Cancer Res 2020 Jun 29;[EPub Ahead of Print], AN Fader, DM Roque, E Siegel, N Buza, P Hui, O Abdelghany, S Chambers, AA Secord, L Havrilesky, DM O'Malley, FJ Backes, N Nevadunsky, B Edraki, D Pikaart, W Lowery, K ElSahwi, P Celano, S Bellone, M Azodi, B Litkouhi, E Ratner, DA Silasi, PE Schwartz, AD SantinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.